Difference between revisions of "Bavituximab (PGN-401)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") Tags: mobile edit mobile web edit |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 10: | Line 10: | ||
[[Category:Immunotherapeutic]] | [[Category:Immunotherapeutic]] | ||
| − | + | ||
[[Category:Anti-PS antibodies]] | [[Category:Anti-PS antibodies]] | ||
Revision as of 19:30, 27 February 2020
Mechanism of action
Binds to phosphatidylserine, provoking an immune response.
Preliminary data
Non-small cell lung cancer
- Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. Epub 2014 Aug 24. link to original article PubMed